[go: up one dir, main page]

WO2019006401A3 - Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof - Google Patents

Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof Download PDF

Info

Publication number
WO2019006401A3
WO2019006401A3 PCT/US2018/040457 US2018040457W WO2019006401A3 WO 2019006401 A3 WO2019006401 A3 WO 2019006401A3 US 2018040457 W US2018040457 W US 2018040457W WO 2019006401 A3 WO2019006401 A3 WO 2019006401A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fusion polypeptides
nucleic acids
recombinant
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/040457
Other languages
French (fr)
Other versions
WO2019006401A2 (en
Inventor
Michael PRINCIOTTA
Robert Petit
Andres A. Gutierrez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sellas Life Sciences Group Ltd
Ayala Pharmaceuticals Inc
Original Assignee
Sellas Life Sciences Group Ltd
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sellas Life Sciences Group Ltd, Advaxis Inc filed Critical Sellas Life Sciences Group Ltd
Publication of WO2019006401A2 publication Critical patent/WO2019006401A2/en
Publication of WO2019006401A3 publication Critical patent/WO2019006401A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des polypeptides de fusion recombinants comprenant un ou plusieurs peptides de protéine tumorale de Wilms (WT1) antigéniques, au moins l'un des peptides WT1 antigéniques étant un peptide WT1 mutant hétéroclitique (par exemple fusionné en peptide contenant du PEST). La présente invention concerne également des acides nucléiques codant pour de tels polypeptides de fusion, des bactéries recombinantes ou des souches de Listeria comprenant de tels polypeptides de fusion ou de tels acides nucléiques, et des banques cellulaires comprenant de telles bactéries recombinantes ou souches de Listeria. La présente invention concerne également des procédés de production de tels polypeptides de fusion, tels que des acides nucléiques, et de telles bactéries recombinantes ou souches de Listeria. La présente invention concerne également des compositions immunogènes, des compositions pharmaceutiques, et des vaccins comprenant de tels polypeptides de fusion, de tels acides nucléiques, ou de telles bactéries recombinantes ou souches de Listeria. L'invention porte également sur des procédés d'induction d'une réponse immune anti-WT1 chez un sujet, sur des procédés d'induction d'une réponse immune anti-tumeur exprimant la WT1 ou anti-cancer exprimant la WT1 chez un sujet, des procédés de traitement d'une tumeur ou d'un cancer exprimant la WT1 ou associé(e) à la WT1 chez un sujet, des procédés de prévention d'une tumeur ou d'un cancer exprimant la WT1 ou associé(e) à la WT1 chez un sujet et des procédés de protection d'un sujet contre une tumeur ou un cancer exprimant la WT1 ou associé(e) à la WT1 à l'aide de tels polypeptides de fusion recombinants, de tels acides nucléiques, de telles souches recombinantes de bactéries ou de souches de Listeria, de compositions immunogènes, de compositions pharmaceutiques ou des vaccins.The invention relates to recombinant fusion polypeptides comprising one or more antigenic Wilms tumor protein (WT1) peptides, wherein at least one of the antigenic WT1 peptides is a heteroclitic mutant WT1 peptide (e.g. fused to PEST-containing peptide). The present invention also relates to nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or nucleic acids, and cell libraries comprising such recombinant bacteria or Listeria strains. The present invention also relates to methods of producing such fusion polypeptides, such as nucleic acids, and such recombinant bacteria or Listeria strains. The present invention also relates to immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. The invention also provides methods for inducing an anti-WT1 immune response in a subject, methods for inducing an anti-tumor immune response expressing WT1 or anti-cancer expressing WT1 in a subject , methods of treating a tumor or cancer expressing WT1 or associated with WT1 in a subject, methods of preventing a tumor or cancer expressing WT1 or associated (e) to WT1 in a subject and methods of protecting a subject against a tumor or cancer expressing WT1 or associated with WT1 using such recombinant fusion polypeptides, such nucleic acids, such recombinant strains of bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions or vaccines.

PCT/US2018/040457 2017-06-30 2018-06-29 Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof Ceased WO2019006401A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527793P 2017-06-30 2017-06-30
US62/527,793 2017-06-30

Publications (2)

Publication Number Publication Date
WO2019006401A2 WO2019006401A2 (en) 2019-01-03
WO2019006401A3 true WO2019006401A3 (en) 2019-04-25

Family

ID=64742275

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/040457 Ceased WO2019006401A2 (en) 2017-06-30 2018-06-29 Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2019006401A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
JP7197481B2 (en) 2016-11-30 2022-12-27 アドバクシス， インコーポレイテッド Immunogenic compositions targeting recurrent cancer mutations and methods of their use
KR102748132B1 (en) 2017-09-19 2025-01-02 어드박시스, 인크. Composition and method for freeze-drying of bacterial or listeria strains
JP2022526011A (en) * 2019-04-10 2022-05-20 エスエルエスジー リミテッド エルエルシー Multivalent immunotherapy composition, use and method for treating WT1-positive cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
US20150352201A1 (en) * 2013-01-15 2015-12-10 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US20160228530A1 (en) * 2014-10-14 2016-08-11 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
WO2016141121A1 (en) * 2015-03-03 2016-09-09 Advaxis, Inc. Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
WO2016191545A1 (en) * 2015-05-26 2016-12-01 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
WO2017087857A1 (en) * 2015-11-20 2017-05-26 Memorial Sloan Kettering Cancer Center Methods and compositions for treating cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
US20150352201A1 (en) * 2013-01-15 2015-12-10 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US20160228530A1 (en) * 2014-10-14 2016-08-11 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
WO2016141121A1 (en) * 2015-03-03 2016-09-09 Advaxis, Inc. Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
WO2016191545A1 (en) * 2015-05-26 2016-12-01 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
WO2017087857A1 (en) * 2015-11-20 2017-05-26 Memorial Sloan Kettering Cancer Center Methods and compositions for treating cancer

Also Published As

Publication number Publication date
WO2019006401A2 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
WO2019006401A3 (en) Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof
US11155588B2 (en) HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
Speiser et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients
KR102046449B1 (en) Yeast-brachyury immunotherapeutic compositions
de Oliveira et al. Design, immune responses and anti-tumor potential of an HPV16 E6E7 multi-epitope vaccine
Fournillier et al. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus
NZ753307A (en) Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
WO2019094607A3 (en) Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
CA2994272C (en) Modified yeast-brachyury immunotherapeutic compositions
Beyaert et al. Vaccine-based immunotherapy for head and neck cancers
MX2019000215A (en) Listeria-based immunogenic compositions comprising wilms tumor protein antigens and methods of use thereof.
Bann et al. Novel immunotherapeutic approaches for head and neck squamous cell carcinoma
Liu et al. Interaction of toll-like receptors with the molecular chaperone Gp96 is essential for its activation of cytotoxic T lymphocyte response
Zehn et al. Inflammation and TCR signal strength determine the breadth of the T cell response in a bim-dependent manner
Assis-Marques et al. Saccharomyces cerevisiae expressing Gp43 protects mice against Paracoccidioides brasiliensis infection
JP2017509642A (en) Medicament for use in a method of inducing or prolonging a cellular cytotoxic immune response
US20220088162A1 (en) Heterologous Prime Boost Vaccine
Rostami et al. Gene and protein delivery using four cell penetrating peptides for HIV‐1 vaccine development
Li et al. Surface display of classical swine fever virus E2 glycoprotein on gram-positive enhancer matrix (GEM) particles via the SpyTag/SpyCatcher system
Farzanehpour et al. HSP70 modified response against HPV based tumor.
Mohit et al. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections
Fonteneau et al. Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells
Song et al. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment
CN100467063C (en) A class of immune adjuvants and their application in the preparation of antiviral vaccines or medicines
Jia et al. A genetically modified attenuated Listeria vaccine expressing HPV16 E7 kill tumor cells in direct and antigen-specific manner

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18822718

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18822718

Country of ref document: EP

Kind code of ref document: A2